Indication
Osteolytic bone metastases of breast cancer
Osteolytic bone metastases of breast cancer represent an advanced skeletal complication occurring when malignant breast epithelial cells disseminate to the bone microenvironment. Read more about Osteolytic bone metastases of breast cancer
11 drugs 10 manufacturers
Drugs that treat it
Common Osteolytic bone metastases of breast cancer therapies.
PAMIDRONATE (pamidronate disodium)
PAMIDRONATE (pamidronate disodium)
PAMIDRONATE (pamidronate disodium)
PAMIDRONATE DISODIUM
PAMIDRONATE DISODIUM
PAMIDRONATE DISODIUM
PAMIDRONATE DISODIUM
PAMIDRONATE DISODIUM
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonOsteolytic bone metastases of breast cancer represent an advanced skeletal complication occurring when malignant breast epithelial cells disseminate to the bone microenvironment.
This clinical state is characterized by tumor-driven disruption of normal skeletal remodeling, where neoplastic cells secrete cytokines such as parathyroid hormone-related protein (PTHrP) that stimulate osteoblasts to express RANK ligand.
This pathway induces pathological osteoclastogenesis and excessive bone resorption, causing localized matrix degradation and osteolytic lesions rather than new bone formation.
The resulting skeletal destruction frequently manifests with intractable bone pain, hypercalcemia of malignancy, pathological fractures, and structural instability such as spinal cord compression.
- nih.gov
Osteolytic bone metastases of breast cancer represent an advanced skeletal complication occurring when malignant breast epithelial cells disseminate to the bone microenvironment This clinical state is characterized by tumor-driven disruption of normal skeletal remodeling, where neoplastic cells secrete cytokines such as parathyroid hormone-related protein (PTHrP) that stimulate osteoblasts to express RANK ligand This pathway induces pathological osteoclastogenesis and excessive bone resorption, ...
- nih.gov
Osteolytic bone metastases of breast cancer represent an advanced skeletal complication occurring when malignant breast epithelial cells disseminate to the bone microenvironment The resulting skeletal destruction frequently manifests with intractable bone pain, hypercalcemia of malignancy, pathological fractures, and structural instability such as spinal cord compression
- nih.gov
This clinical state is characterized by tumor-driven disruption of normal skeletal remodeling, where neoplastic cells secrete cytokines such as parathyroid hormone-related protein (PTHrP) that stimulate osteoblasts to express RANK ligand This pathway induces pathological osteoclastogenesis and excessive bone resorption, causing localized matrix degradation and osteolytic lesions rather than new bone formation
- nih.gov
The resulting skeletal destruction frequently manifests with intractable bone pain, hypercalcemia of malignancy, pathological fractures, and structural instability such as spinal cord compression
Personalize your experience
Follow Osteolytic bone metastases of breast cancer and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.